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Abstract
Background: Adenosine-to-inosine (A-to-I) RNA editing is an essential post-transcriptional mechanism mediated by
ADAR enzymes that have been recently associated with cancer.
Results: Here, we characterize the inosinome signature in normal brain and de novo glioblastoma (GBM) using
new metrics that re-stratify GBM patients according to their editing profiles and indicate this post-transcriptional
event as a possible molecular mechanism for sexual dimorphism in GBM. We find that over 85% of de novo GBMs
carry a deletion involving the genomic locus of ADAR3, which is specifically expressed in the brain. By analyzing
RNA editing and patient outcomes, an intriguing gender-dependent link appears, with high editing of Alus shown
to be beneficial only in male patients. We propose an inosinome-based molecular stratification of GBM patients that
identifies two different GBM subgroups, INO-1 and INO-2, which can identify novel high-risk gender-specific patient
groups for which more aggressive treatments may be necessary.
Conclusions: Our data provide a detailed picture of RNA editing landscape in normal brain and GBM, exploring
A-to-I RNA editing regulation, disclosing unexpected editing implications for GBM patient stratification and
identification of gender-dependent high-risk patients, and suggesting COG3 I/V as an eligible site for future
personalized targeted gene therapy.
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Background
Genomic instability and increased DNA mutation fre-
quency provide selective advantages for clonal multiplica-
tion of cancerous cells. More than 100 oncogenes have
been identified so far, but only a small subset has been con-
sistently classified as cancer driver genes [1, 2]. Altogether,
alterations affecting genes able to modulate RNA expres-
sion, cell differentiation, and recoding genomic messages
are recognized as important factors for cancer progression.
Interestingly, an essential post-transcriptional mechanism,
A-to-I RNA editing, is able to modulate all the above mo-
lecular pathways, and for this reason, increasing attention
has been paid to this mechanism in cancer field [3, 4].
RNA editing has a critical role in superimposing
novel/additional information to the genetically
hard-wired transcriptome [5]. The most common type
of RNA editing in humans consists in A-to-I nucleotide
conversion within double-stranded RNA (dsRNA) mole-
cules catalyzed by the adenosine deaminases that act on
the dsRNA (ADARs) family of enzymes. ADAR1 (also
known as ADAR) and ADAR2 (also known as ADARB1)
are active and ubiquitously expressed enzymes [5], while
ADAR3 (also known as ADARB2) is inactive and mainly
expressed in the brain, where it seems to regulate the
editing activity of the other two ADARs [6, 7]. Inosines
are recognized as guanosines by splicing and transla-
tional machineries ultimately leading to diversification of
both the transcriptome and proteome landscapes [8].
So far, it has been estimated that over 4.7 million edit-
ing sites exist in the human transcriptome, involving
* Correspondence: angela.gallo@opbg.net
1RNA Editing Lab., Oncohaematology Department, IRCCS Ospedale Pediatrico
“Bambino Gesù”, Viale San Paolo, 15 00146 Rome, Italy
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Silvestris et al. Genome Biology           (2019) 20:33 
https://doi.org/10.1186/s13059-019-1647-x
both coding and non-coding RNAs [8–10]. ADARs are
essential enzymes in mammals [11, 12]; however, it re-
mains to be defined which editing sites are necessary for
cell homeostasis and survival or important in cancer
[13–15].
Parallel advances in computational methods and
high-throughput RNA sequencing have supported the
massive identification of RNA editing sites, demonstrat-
ing that the vast majority of editing in humans occurs
within the primate-specific Alu-inverted repeat ele-
ments, due to their tendency to form dsRNA secondary
structures, substrates recognized by ADAR enzymes [16,
17]. Virtually, all adenosines within Alu repeats are edi-
ted, mostly to a low degree (< 1%) [16]; however, specific
sites (such as non-repetitive or recoding sites) can be
edited at high level, with GRIA2 Q/R site being an ex-
ample of a highly edited site in the brain (~ 100% edit-
ing) [11].
Recent studies, mainly conducted thanks to The Can-
cer Genome Atlas (TCGA) project, have characterized
the RNA editing landscape of various cancer types in a
systematic way [14, 18, 19]. These studies, searching for
common editing features among cancer types, revealed
many altered A-to-I RNA editing events in tumor sam-
ples relative to the normal tissues.
Herein, we specifically focused on de novo/primary
glioblastoma (GBM), normal brain, and astrocytes in a
robust and integrated study analyzing these samples in
detail at post-transcriptional level also combining gen-
omic/transcriptional data, thus providing an alternative
approach to stratify GBM patients (INO-1 and INO-2)
and revealing novel findings potentially critical for future
personalized therapies. Of note, de novo GBM is the
most common and deadly primary brain tumor in
humans developing from glial cells, for which more ef-
fective therapeutic interventions are urgently needed
[20]. The vast majority of GBMs (~ 90%) develop rapidly
as observed in de novo GBMs, while the less frequent,
secondary GBMs progress from lower-grade astrocyto-
mas. In order to elucidate de novo GBM-specific RNA
editing signature, we analyzed RNA-Seq from 145 pri-
mary GBMs (TCGA dataset) compared to 132 RNA-Seq
(GTEx project) from normal brain cortex and to 12
pools of primary astrocytes which represent the majority
of glial cells in the brain. Additionally, we also confirmed
our major results in a second independent data set of
glioblastomas (CGGA).
For the first time, our study characterizes GBM inosi-
nome in a comprehensive and transcriptome-wide man-
ner, disclosing a strong and peculiar perturbation of
inosinome landscape in GBM compared to normal brain
never described before and involving all the three ADAR
proteins as tested in two independent de novo GBM co-
horts of patients (TCGA and CGGA). Most importantly,
we showed that the editing signature can stratify GBM
patients and identify gender-dependent high-risk pa-
tients never reported before. Altogether, our findings
provide novel insights into A-to-I RNA editing regula-
tion and GBM pathogenesis.
Results
Comprehensive A-to-I RNA editing analysis showed a
consistent decrease in editing activity in de novo GBM
compared with both normal brain and primary astrocytes
We started by studying the similarities and distances
among de novo GBMs (145 samples), normal brain tis-
sues (132 samples), and primary astrocytes (12 inde-
pendent pools) based on editing profiles by applying a
non-metric multi-dimensional scaling (N-MDS) method
based on Spearman’s rank correlation coefficients. We
showed that de novo GBM inosinomes always clustered
as a distinct and independent group compared to either
the brain cortex or astrocyte samples, being more similar
to normal brain tissues than astrocytes (Fig. 1a).
Global editing activity mainly concentrates on Alu se-
quences; therefore, we initially focused on quantifying
editing within Alus in order to explore the global editing
pattern among samples. We calculated the Alu editing
index (AEI) and then compared the different distribu-
tions. Of note, the AEI corresponds to the weighted
average editing level across all the expressed Alu se-
quences [21]. Applying this metric, we found a strong
editing decrease in GBMs compared to normal brain
samples (median values GBM = 0.73% and brain cortex
= 1%, p < 0.0001) (Fig. 1b; Additional file 1: Table S1).
We then extended our analysis to the sites located in
hyper-edited regions (i.e., repetitive RNA portions with
clusters of multiple edited adenosines) that are undetect-
able by standard alignment methods [22], finding that
cancer samples are significantly under-edited also in
these regions (Fig. 1c; Additional file 1: Table S1).
Hyper-editing values were not tested in astrocyte pools
due to the low number of potentially supporting reads
per sample required for this specific analysis.
While most editing sites are located within Alu-in-
verted repeats, several editing events occur in
non-repetitive regions of RNAs, with some of them lead-
ing to amino acid substitutions (recoding sites) often
present in key neuronal gene transcripts [23]. The latter
sites are potentially highly informative as they are more
likely to have a functional role in cancer. In order to
quantify the overall fluctuations of editing levels at those
sites, we introduced a novel, ad hoc, metrics for the un-
biased measure of global editing at non-repetitive and
recoding sites, generating two indexes that we named
“non-repetitive editing index” (nREI) and “recoding edit-
ing index” (REI). These indexes represent the weighted
Silvestris et al. Genome Biology           (2019) 20:33 Page 2 of 18
average editing levels at all known non-repetitive and re-
coding sites, respectively.
Applying these new metrics, we found that overall
editing, also at non-repetitive and recoding sites, was
significantly and strongly decreased in GBMs compared
to either the brain cortex or astrocytes (nREI median
values GBM = 3.94%, cortex = 10.03%, astrocytes pools
= 13.2%; REI median values GBM = 4.18%, cortex =
11.15%, astrocytes = 7.82%, p < 0.0001) (Fig. 1d, e; Add-
itional file 1: Table S1).
An additional RNA-Seq data generated from an inde-
pendent non-overlapping de novo GBMs cohort, the
Chinese Glioma Genome Atlas (CGGA) [24], was also
utilized to validate our findings. Indeed, we report that
Fig. 1 Inosinome signature in de novo GBM compared to the normal brain and astrocytes. a Two-dimensional non-metric multi-dimensional
scaling (N-MDS) ordination plots of GBM (145 samples, shown in red), cerebral cortex (132 samples, shown in blue), and normal astrocytes (12
different pools, shown in green). b Alu editing index (AEI) distributions (box plot, median). c Distributions of hyper-editing sites (box plot, median
and mean values indicated as a black bar and white dots, respectively). d Non-repetitive editing index (nREI) value distributions (box plot,
median). e Recoding editing index (REI) values distributions (box plot, median). Two-tailed Mann-Whitney U test was applied. ****p≤ 0.0001
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in both the de novo GBM cohorts (TCGA and CGGA),
the editing levels, as measured by the different indexes
(AEI, nREI, and REI), significantly decreased in tumor
compared to the normal brain (Additional file 2: Figure
S1a).
Taken together, our results demonstrate that de novo
GBMs have a distinct inosinome profile compared to
both normal brain and astrocytes (the most abundant
fraction of glial cell types in the brain) characterized by
a strong and global editing decrease affecting different
positions: Alus, hyper-edited, non-repetitive, and recod-
ing sites.
Changes in RNA editing patterns at recoding sites in
GBMs relative to normal samples: re-shaping the RNA
editing signature at recoding sites
Considering the possible relevant importance of recod-
ing editing sites in cancer [25], we specifically focused
on these sites. We systematically searched for significant
alterations of editing in recoding sites in the brain and
GBM finding that among the 397 informative recoding
positions (supported by at least 10 reads/site and with ≥
1% editing), only 178 sites were found significantly dif-
ferently edited in GBM compared to the normal brain
(Additional file 3: Table S2, two-tailed Mann-Whitney U
test followed by Benjamin-Hochberg multiple test cor-
rection). Among these, 89 sites were localized in
non-repetitive regions (identified in Additional file 3:
Table S2 as NONREP), 79 sites in Alu repeats (identified
as ALU), and only 10 sites in repetitive (identified as
REP) non-Alu regions (i.e., LINE, non-Alu SINEs) (Add-
itional file 3: Table S2).
We report that > 93% (166/178) of the identified re-
coding sites were significantly under-edited in GBM,
with only 12/178 sites showing an increased editing level
(Additional file 3: Table S2). Additionally, among the 12
over-edited sites in GBM, 10 sites showed a slight edit-
ing increase in GBM ranging from 1 to 5% Δ medians
(Additional file 3: Table S2) and only 2 sites displayed an
editing increase > 15% Δ medians in GBMs compared to
the normal brain: COG3 I/V and CADPS E/G (both with
Δ medians = 17%) (Additional file 3: Table S2).
Editing levels at the 89 recoding sites in non-repetitive
regions were shown as a heatmap with a clear and gen-
eralized decrease of editing frequency in GBMs com-
pared to the normal brains (Fig. 2a). Few positions (such
as GRIA3 R/G, GRIA2 Q/R, and NEIL1 K/R sites) highly
edited in the brain resisted better than other sites to the
generalized editing decrease phenomenon/scheme,
retaining editing at levels similar to those observed in
the normal brain (Fig. 2a, b; Additional file 3: Table S2).
The few recoding sites being more edited in GBM (i.e.,
COPA I/V, COG3 I/V, and CADPS E/G) were marked in
the heatmap (Fig. 2a, b; Additional file 3: Table S2).
We validated by Sanger sequencing the editing level at
the COPA I/V, COG3 I/V, and CADPS E/G sites in de
novo GBMs and the normal brain cortex (Additional file 2:
Figure S2a). Additionally, we reported that these sites were
all edited by ADAR2, as tested in HEK293T and U87-MG
GBM cell lines (Additional file 2: Figure S2b).
Editing at the 89 recoding sites in non-repetitive re-
gions encompassed 65 different transcripts. We found
that 83% of the differentially edited transcripts were also
aberrantly expressed in GBMs, with 63% of them (41/
65) being both under-edited and down-expressed in de
novo GBM (Additional file 2: Figure S3).
Overall, our data showed that transcripts carrying re-
coding editing sites were generally under-edited and
under-expressed in de novo GBM compared to normal
brain tissue. However, a few specific recoding sites dis-
played higher editing levels in tumor tissues, suggestive
of a possible pro-tumoral role in GBM.
Functional effects of the COG3 I/V editing site in GBM
A few recoding sites are highly edited in GBM compared
to the normal brain with the top positions being COG3 I/
V and CADPS E/G (with > 15% editing increase in cancer)
(Fig. 2 and Additional file 3: Table S2). We first tested if
editing at these sites was associated with patient overall
survival (OS), finding that only the COG3 I/V site, and not
the CADPS E/G site, was significantly associated with pa-
tients’ OS (p < 0.044) (Fig. 3a). Specifically, a higher editing
level (≥ 40%) at this site is associated with a worse progno-
sis, suggesting COG3 I/V over-editing as a possible
pro-tumoral event (considering 20% median editing in
normal brain, see Additional file 3: Table S2).
We then investigated the possible biological functional
role played by COG3 I/V editing in GBM. We expressed
COG3 in its unedited (uned) or edited (ed) versions in
three different glioblastoma cell lines (A172, U87-MG,
and U118-MG), and cell proliferation and migration
were tested (Fig. 3 and Additional file 2: Figure S4). We
found that only the edited COG3 (edited at I/V site) sig-
nificantly enhanced the invasive/proliferative behavior in
all these three cell lines compared to the unedited coun-
terpart (Fig. 3 and Additional file 2: Figure S4).
Altogether, our data indicated that over-editing (≥
40%) at the COG3 I/V site plays a critical pro-tumoral
role in GBM and correlates with a worse prognosis in
GBM patients.
ADAR expression is altered in GBMs and correlated with
editing indexes, age, and gender in the normal brain
Editing fluctuations/alterations may be accounted to the
deregulation of RNA editing enzyme (ADAR) expres-
sion; therefore, we estimated ADAR levels in the normal
brain and de novo GBMs by using the Cuffquant/Cuff-
diff2 pipeline. We found that ADAR1 is less expressed,
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although not significantly, in de novo GBMs compared
to controls (Fig. 4a). Of note, by applying the
Kolgomorov-Smirnov test, which quantifies the distance
between distributions, ADAR1 FPKM values in the brain
cortex and GBM were indeed significantly different (p =
7.255e−10). Differently from ADAR1, both ADAR2 and
ADAR3 were found strongly downregulated in GBMs
(p ≤ 0.0001, Fig. 4a). Notably, the ADAR expression pat-
tern as found in de novo GBM of TCGA was also found
in a different and independent de novo GBM patient co-
hort (CGGA) (Additional file 2: Figure S1b).
Next, we asked whether there could be a correlation
between ADAR expression (FPKMs) and editing level in
terms of AEI, nREI, and REI indexes. According to both
the Spearman and the Pearson tests, we found a positive
correlation in both cerebral cortex (i.e., Pearson r = 0.39,
p < 0.0001) and GBMs (i.e., Pearson r = 0.23, p = 0.004)
only when we associated AEI and ADAR1 (Fig. 4b). In
the normal cortex, the recoding editing index (REI) posi-
tively correlated (i.e., Pearson r = 0.28, p < 0.0001) with
ADAR2, while it is inversely associated with ADAR3 (i.e.,
Pearson r = − 0.26, p = 0.0025) (Fig. 4b, TCGA). The
Fig. 2 Editing fluctuation in de novo GBM and normal brain at coding sites. a Heatmap of RNA editing levels at recoding sites in GBM compared
to the normal cerebral cortex. Each column represents one of the 145 de novo GBMs (TCGA) and 132 brain cortex (GTEx) samples, rows show the
89 differentially edited non-repetitive recoding sites. Only the statistically significant sites (two-tailed Mann-Whitney U test, with Benjamini-
Hochberg-corrected p value ≤ 0.05) are shown. The heatmap was generated with Pandas and Seaborn Python libraries, and the list of the editing
sites was also reported in the same order in Additional file 3: Table S2. b Box plots representing editing frequencies (%) distributions in GBM and
brain cortex at selected sites (two-tailed Mann-Whitney test, with Benjamini-Hochberg correction): GRIA3 R/G q value = 6.44E−33, GRIA2 Q/R q
value = 8.63E−20, NEIL1 K/R q value = 1.01E−16, COPA I/V q value = 0.0022, COG3 I/V q value = 0.0002, and CADPS E/G q value = 2.58E−18. In red
GBM and in blue normal brain cortex samples are shown. Medians are indicated by black bars
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above results were also recapitulated in the CGGA GBM
dataset (Additional file 2: Figure S5). These findings are
intriguing as they suggested that editing, within Alus, re-
produces the ADAR1 level, while editing at recoding
sites directly correlates with ADAR2 and is negatively in-
fluenced by ADAR3.
We then looked for possible associations between
ADAR expression and patients’ clinical data, such as age,
gender, and OS, by applying both Spearman’s and Pear-
son’s correlation tests. We report that both ADAR1 and
ADAR2 negatively correlated with age in healthy people,
with the ADARs being less expressed in elderly subjects
(Fig. 4c, d); however, we found that ADAR3 displayed an
opposite trend by being over-expressed in older subjects
(Fig. 4e). Most interestingly, when we evaluated whether
these correlations were gender-dependent, we found that
ADAR3 positively and significantly correlated only when
male patients were considered (Fig. 4f and Add-
itional file 2: Figure S6). Of note, no gender-dependent
differences were observed when ADAR1/2 were consid-
ered (Additional file 2: Figure S6). Importantly, the cor-
relations between ADAR expression and age/gender of
patients were always lost when GBM samples were ana-
lyzed (Fig. 2c–f and Additional file 2: Figure S6).
In summary, we found that ADAR expression is de-
creased in GBM, matching with the overall editing re-
duction in this cancer compared to the normal brain,
with ADAR1 directly correlating with AEI and ADAR2
directly associated with REI values. Interestingly, ADARs
significantly associate with age/gender only in healthy
individuals, while all these correlations were absent in
GBMs.
Fig. 3 Clinical relevance of editing at COG3 I/V recoding site. a Kaplan-Meier curves representing the survival probability of GBM patients stratified
by COG3 I/V (104 samples) and CADPS E/G (108 samples) editing levels respectively. Log-rank test, COG3 p value = 0.044, CADPS p value = 0.56.
The red line represents high editing frequency (≥ 40%), the green line represents low editing frequency (< 40%). b Migration assay of
glioblastoma cells (A172) expressing unedited COG3 (uned) and edited (ed) COG3 was performed 24 h post-seeding. Representative photographs
of migrated cells are shown (× 4 and × 10 magnifications). Migrated cells were stained with Diff-Quick and counted. Histograms show the
migration ability of ed. COG3 expressing cells relative to the uned COG3 (fold increase ± SD, n = 3) **p≤ 0.01 (two-sided t test). c Proliferation
(MTS assay) of glioblastoma cells (A172) infected with unedited or edited COG3 (mean ± SD, n = 3) **p ≤ 0.01 (two-sided t test)
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ADAR3 is deleted in de novo GBM
To investigate whether the decreased ADAR expression
was due to DNA mutations or copy number variations
(CNVs), we analyzed 145 GBM samples, included in our
study, through the cBioPortal web tool with regard to
variant calling Gistic2.0 CNV data generated by TCGA.
No relevant mutations were observed within ADAR
genes (data not shown); however, by analyzing for pos-
sible gene copy number variations, we found that > 85%
of de novo GBMs tested carry an ADAR3 deletion (with
85.1% hemizygous and 1.41% homozygous deletions) at
the 10p15.3 genomic locus (Fig. 5a).
We validated these findings through qRT-PCR (data
not shown) and by IHC performed on the normal brain
and adult GBMs (Fig. 5b). Specifically, ADAR3 was
found expressed in neuronal and glial cells (i.e., thal-
amus) while it was totally absent (0% positive cells) in
the GBM tissues analyzed (Fig. 5b).
Fig. 4 ADAR expression correlates with editing indexes, age, and gender. a ADAR1, ADAR2, and ADAR3 expression levels were calculated by using
Cufflinks (FPKM distributions), ****p≤ 0.0001. b Correlations between ADAR expressions and editing indexes (AEI and REI) in TCGA GBM cohorts
and the normal brain. c–e Correlations between ADAR expression (FPKM) and age (in blue healthy individuals in red GBM patients). f Correlation
between ADAR3 expression (FPKM) and male’s age. **p≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001
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Overall, the downregulation of ADAR3 as found in de
novo GBMs is mainly accounted to a gene copy number
alteration (deletion) in cancer.
AEI associated with GBM patient’s overall survival in a
gender-specific manner
Considering the important overall impact of RNA edit-
ing on cancer [15, 26–28], we asked whether inosinome
might correlate with patients’ clinical parameters such as
OS, age at diagnosis, or the Karnofsky Performance
Score (KPS).
Firstly, we investigated whether the AEI, REI, and nREI
indexes may represent predictive indexes for the pa-
tient’s outcome. Kaplan-Meier curves demonstrated that
a significant correlation existed between AEI and pa-
tients’ OS with an opposite trend in females and males:
a high AEI index (AEI > 0.0078, lines in red) correlated
with a good prognosis only in males, while a lower Alu
index (AEI ≤ 0.0078, lines in blue) was predictive of
poorer outcome (Fig. 6a). In females, on the other hand,
a lower Alu editing index (AEI ≤ 0.0080, lines in blue) is
a reliable favorable prognostic factor associated with a
better OS (Fig. 6b). The different gender-dependent
trends of the KMs generated by AEI stratification were
also observed in an independent RNA-Seq data of de
novo GBM cohort (CGGA) (Additional file 2: Figure
S7).
Next, univariate and multivariate tests were performed
to estimate the independent effect of AEI with other fac-
tors predicted to be important in the OS of glioblastoma
patients (males and females). We showed that factors,
including TP53 status, IDH1/2 status, and AEI, were sig-
nificantly associated with the OS of GBM male patients,
whereas just the AEI came out as the only factor to be
linked to the OS in female patients (Fig. 6c). Multivariate
Cox regression analysis, which investigates how factors
such as TP53 mutations, IDH1/2 status, MGMT pro-
moter methylation, Chr7 Gain/Chr10 loss, and AEI
jointly affected survival, was also performed. Our ana-
lysis indicated that AEI was an independent prognostic
factor for GBM OS in male patients, demonstrating that
patients with a high AEI have a significantly decreased
risk of death (HR, 0.278; p = 0.0217) (Fig. 6c).
Overall, our data demonstrated that a high Alu editing
index (AEI) positively correlates with a better patient
outcome (OS) in males; however, particular attention is
necessary for female GBM patients that survive less with
a high AEI.
Editing signature did not match with the TCGA-proposed
GBM subclassification
GBMs were stratified into different subtypes based upon
patterns of genomic mutations and gene expression [29,
30]. In order to see whether genetic and epigenetic
events (such as RNA editing) might coincide, we investi-
gated if RNA editing signature can overlap with the
well-known glioblastoma subtypes (i.e., classical (CL),
mesenchymal (M), neural (N), and proneural (PN) [29]).
A hierarchical clustering based on Spearman’s correl-
ation coefficients was applied and calculated by pairwise
comparisons of RNA editing levels among GBM sub-
types (CL, M, N, PN). Clustering was performed consid-
ering all the editing positions together. Interestingly,
proneural GBMs are clustered as a different group to
the others (Fig. 7a). In order to identify the sites respon-
sible for the inosinome-based proneural separation, we
performed all the possible site-by-site pairwise compari-
sons of editing levels among GBM subtypes focusing on
non-repetitive sites and selected those that resulted sig-
nificant (two-tailed Mann-Whitney U test) in at least 1
Fig. 5 ADARs copy number variation in de novo GBMs. a ADAR genes copy number variation plot (cBioPortal, GISTIC2.0 algorithm). b Two
representative pictures of six GBMs and two normal brains stained with ADAR3 by IHC (× 20 and × 40 magnifications are shown)
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comparison. We identified 16 positions in 9 different
genes (Additional file 4: Table S3 and Additional file 2:
Figure S8). These sites were then used to calculate an ad
hoc index, herein identified as “differential editing index”
(DEI), that shows editing differences among known
GBM subgroups (Fig. 7b, two-tailed Mann-Whitney U
test). We also analyzed editing indexes (AEI, nREI, REI)
per subtype; however, no significant differences were ob-
served when using these indexes according to a
two-tailed Mann-Whitney U test (data not shown).
GBM subtypes were also analyzed taking into account
the gene expression signatures by means of
Jensen-Shannon distance based on all the differently
expressed genes. Once more, two distinct gene expres-
sion profiles were identified: one enriched with pro-
neural subtype and the other including the three
remaining subtypes (Fig. 7c).
Overall, our data showed that GBM inosinome signa-
ture did not correspond with GBM subclassification
based on gene expression and mutational analysis (CL,
M, N, PN), thereby suggesting that GBM is a highly
multifaceted disease in which several layers of molecular
information (including genetic and epigenetic) should be
considered.
Inosinome-based GBM patients stratification identifies a
novel gender-dependent high-risk patient subgroup
Rigorous editing analysis of de novo GBMs was con-
ducted in order to stratify patients by their RNA editing
signatures. We first collected all the editing positions be-
ing detected in at least 140 GBMs that were further se-
lected for positions laying within exons, introns,
5′-3′-UTRs (Additional file 5: Table S4); we then used
the retained positions to calculate an Euclidean sample
distance matrix with the resulting unsupervised hier-
archical clustering, showing that GBMs can be classified
into 2 distinctive subgroups: the GBM-Inosinome-group
1 (here indicated as INO-1) characterized by a higher
editing signature and the GBM-Inosinome-group 2 (here
indicated as INO-2) with an overall lower editing level
(Fig. 8a). Editing index (AEI, nREI, and REI) distribu-
tions in INO-1 and INO-2 GBMs were significantly dif-
ferent (AEI and nREI p = 0.0001; REI p = 0.01)
(Additional file 2: Figure S9a).
Interestingly, INO-1 GBM female patients are charac-
terized by a worse prognosis (OS) compared to the
INO-2 female subgroup (p = 0.018) (Fig. 8b). No differ-
ences in OS were found when we analyzed only males or
all the GBM patients together (data not shown). The
new female GBM stratification (INO-1/2) was also ob-
served by analyzing an independent de novo GBM co-
hort (CGGA) (Additional file 2: Figure S10).
Multivariate Cox regression analysis was also per-
formed to investigate whether factors such as TP53 mu-
tations, IDH1/2 status, MGMT promoter methylation,
Chr7 Gain/Chr10 loss, and INO subgroup jointly af-
fected survival. Our analysis indicated that the INO pa-
tient’s stratification is an important prognostic factor for
GBM female patients (HR, 3.2E+ 00; p = 0.014) (Fig. 8c).
Among the top differently edited positions identified
in female INO-1 and INO-2 (with at least 15% Δ me-
dian, Additional file 6: Table S5), there were three edit-
ing positions all located within the same transcript
identified as proteasome subunit beta type 2 (PSMB2).
Fig. 6 AEI associated with GBM patients overall survival in a gender-specific manner. a, b Gender-dependent association between Alu editing and
OS in male and female GBM patients. Females and males exhibit an opposite trend when stratified using AEI. c Prognostic factors associated with
OS in the Cox hazard regression analysis for de novo GBM patients from TCGA, univariate, and multivariate analyses are shown for male (left) and
female (right), respectively
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Interestingly, these three Alu sites are located within the
3′-UTR of PSMB2 and were all significantly associated
with patients’ outcome in females only, with higher edit-
ing correlating with a negative prognosis in these pa-
tients (Fig. 8d). We found a significant and direct
correlation between PSMB2 expression and editing only
when female patients were considered (Additional file 2:
Figure S11).
The editing-based molecular classification proposed
(INO-1 and INO-2) was further analyzed by gene ex-
pression and mutational signature (Fig. 9 and Add-
itional file 7: Table S6). We found that INO-1 GBMs
shows upregulation of genes mainly involved in meta-
bolic pathways such as the D-amino acid oxidase (DAO),
the phosphoglycerate mutase 2 (PGAM2), and the indo-
leamine 2,3-dioxygenase 1 (IDO1) as well as genes of im-
munological signature, such as the signal transducer and
activator of transcription 1 (STAT1) or the interferon
regulatory factor 9 (IRF9) (Fig. 9 and Additional file 7:
Table S6). Of note, both STAT1 and IRF9 can upregulate
ADAR1 [31], and indeed, patients laying in INO-1 sub-
group, characterized by a high expression of STAT1 and
IRF9, also showed an increased level of ADAR1 (Add-
itional file 2: Figure S9b).
INO-2 GBM subgroup is characterized by genes be-
longing to the p53-pathway (such as MDM2/4 and
CCND1) and by the upregulation of important genes
such as PDGFRA, IGF2, and VEGFA and genes coding
for nucleosome proteins (Fig. 9 and Additional file 7:
Table S6).
Mutational profiles of GBM-INO-1 and GBM-INO-2
showed that GBMs with the majority of the TP53 and
EGFR mutations belonged to the INO-2 subgroup, in
which we also reported higher presence (> 70% GBMs)
of mutations within TTN gene. Of note, the analysis of
differently expressed genes in INO-1 and INO-2 females
showed that INO-1 patients have a high level of IFITM1,
IDO1, and EGFR (Additional file 7: Table S6).
In summary, we described an inosinome-based mo-
lecular stratification of GBM patients that identifies two
different subgroups (based on editing, gene expression,
and mutational analysis), i.e., INO-1 and INO-2, which
could be clinically relevant for the identification of
gender-dependent high-risk GBM patients.
Discussion
Our study provides a transcriptome-wide
characterization of RNA editing across de novo GBM
samples and shows that A-to-I RNA editing and the en-
zymes mediating this modification are significantly al-
tered in this aggressive brain cancer. By correlating the
inosinome-based data, ADAR expression, and patient
features/outcome, we depicted the GBM inosinome
landscape that indicates RNA editing as an exciting field
Fig. 7 Inosinome signature did not overlay the previously proposed
GBM subclassification. a Heatmap of clustered correlation matrix
based on Spearman’s coefficients considering all the editing
positions detected in proneural (PN, shown in blue), mesenchymal
(M, shown in purple), neural (N, shown in orange), and classical (CL,
shown in green) GBM subtypes. b Distributions of editing index
(DEI) calculated at the differentially edited sites identified among
GBM subtypes (see Additional file 4: Table S3). c Dendrogram plot
representing Jensen-Shannon distances based on gene expression
levels (cummeRbund software). ****p≤ 0.0001,
***p ≤ 0.001, **p≤ 0.01
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of investigation for discovering alternative mechanisms
clinically relevant for GBM patients and important for
the RNA editing machinery in the brain.
A clear separation between cancer and normal samples
(either tissues or cells) was observed based on their dis-
tinctive editing profiles. The origin of such differences
involved all the editing positions in the transcriptome:
Alus, non-repetitive, and recoding sites. We generated
novel metrics to obtain an unbiased and robust measure
of editing frequencies at non-repetitive (nREI index) and
recoding (REI index) sites that, together with the AEI
(Alu editing), showed an overall marked reduction of
editing frequency in GBMs compared to normal sam-
ples. Among the recoding sites, 178 positions were
found differentially edited with a > 93% of sites found
under-edited in GBMs, thus expanding, on a larger scale,
what was previously observed at a few specific sites [32–
34]. The GRIK2 Q/R, Y/C, and GABRA3 I/M sites
emerged as sites with a remarkable editing decrease in
GBM (with an editing drop ranging from − 82 to − 74%
Δ medians) followed by GLI1 R/G site (− 27% Δ me-
dians), the latter playing a key role in modulating the
Hedgehog (HH) signaling in cancer [35]. The GRIA2 Q/
R (− 14% Δ medians) site, being less edited in GBM,
Fig. 8 GBM patient stratification based on inosinome signature identifies two subgroups. a Unsupervised hierarchical clustering (based on
Euclidean samples distance matrix) and heatmap (editing levels) calculated on the editing positions detected in at least 140 GBMs. b Kaplan-
Meier curves representing the OS of GBM female patients stratified by INO-1 and INO-2. c Prognostic factors associated with the OS of de novo
GBM female patients (TCGA) are analyzed with the Cox hazard regression, both univariate and multivariate analysis are shown. d Editing
frequency distributions within 3′-UTR of PSMB2 in female GBM patients and Kaplan-Meier curves based on high/low editing at the PSMB2 sites in
female GBM patients
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appeared quite “resistant” to a generalized editing de-
crease tendency. Despite the global editing loss observed
in GBM, we found that a few recoding sites (12 sites)
were over-edited in cancer, with the top sites being
CADPS E/G (+ 17% Δ medians) and COG3 I/V (+ 17% Δ
median). Both of these sites were localized in transcripts
conserved during evolution (PHAST conservation score
from 46 species ~ 700/1000) and involved in
neuro-trafficking and exocytosis pathways [36, 37].
A recent pan-cancer study identified an appreciable
number of RNA editing sites with potential clinical im-
plications (AZIN1, COG3, and GRIA2) [18]. Our study
further expands this observation and provides evidence
that the specific RNA editing event within the COG3 I/
V site, particularly enriched in malignant gliomas, is
pro-tumoral in glioblastoma cells boosting both prolifer-
ation and migration. Previous studies on large-scale
RNA editing analyses, mostly using TCGA data, demon-
strated an overall increased editing activity mainly due
to ADAR1 [14, 18, 19], due to 1q amplification (chromo-
some where ADAR1 lays), and/or due to the cancer
inflammation state (ADAR1 is an interferon-responsive
enzyme) [19]. Herein, we demonstrated that in de novo
GBM, ADAR levels were profoundly altered with a
strong decrease of ADAR2 and ADAR3, both of which
are significantly connected (even if with opposite trends)
with the REI (editing at recoding sites) at least in normal
brain and ADAR1 correlating with the loss of AEI. The
genomic alteration involving ADAR3 was pervasive in
GBM (> 85% deletion), but further investigations are re-
quired to dissect the interplay of ADAR3 genomic loss
and RNA editing perturbation in this cancer. The
Kaplan-Meier analysis demonstrated that Alu editing is a
prognostic factor in GBM in a gender-dependent man-
ner, with high AEI representing a positive prognostic
factor for male patients (66.2% of the 145 GBM patients
analyzed) but becoming a negative factor in female pa-
tients. This finding supported a previous study which
also indicated AEI as an important prognostic factor al-
though in different cancer types [14].
Most importantly, we assessed the independent value
of AEI with other variables known to be important for
Fig. 9 Gene expression profiles of INO-1 and INO-2 subtypes. a Heatmap showing the top differentially expressed genes between INO-1 and
INO-2 GBM subtypes (Additional file 7: Table S6) in dark yellow listed some highly expressed genes in INO-1 and in light yellow the highly
expressed genes in INO-2. b Mutational analysis of the most frequently altered genes in INO-1 and INO-2 GBM subgroups
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the OS of glioblastoma patients. Factors including TP53
status, MGMT promoter status, Chr7gain/Chr10loss,
and IDH1/2 status were associated with the OS of GBM
patients; interestingly, a Cox regression analysis includ-
ing the above factors plus AEI showed that the editing
index is indeed an independent prognostic factor for
GBM OS in male patients, thereby demonstrating that
male patients with a high AEI have a significantly de-
creased risk of death (HR, 0.278; p = 0.0217).
Intriguingly, based on the inosinome signature, we
showed that de novo GBM patients can be stratified into
two novel major subgroups: the GBM-Inosinome-group
1 (herein identified as INO-1 subgroup) including GBMs
with a higher editing profiles and the
GBM-Inosinome-group 2 (INO-2 subgroup) enriched of
GBMs with a low editing signature at specific sites. The
proposed novel INO-1 and INO-2 GBM subgroups also
have distinctive gene expression profiles and mutational
schemes; upregulation of genes such as PGAM2, IDO2,
STAT-1, IRF9, ADAR1, and HLA-E/A in INO-1; and up-
regulation of PDGFRA, IGF2, VEGFA, FGF18, and
MDM2/4 in INO-2, the latter also showing a high fre-
quency of mutations in TTN, MUC16, EGFR, and TP53.
Importantly, female patients belonging to INO-1 have a
bad prognosis (OS) compared to the INO-2 female sub-
group (p = 0.018).
We showed that the INO subtype is a prognostic fac-
tor for GBM female patients (HR, 3.2E+ 00; p = 0.014) in
a multivariate Cox regression analysis when TP53 muta-
tions, IDH1/2 status, MGMT promoter methylation,
Chr7 Gain/Chr10 loss, and INO subtype were jointly
analyzed.
The intriguing gender-dependent editing signature,
already found when AEI-KM was analyzed and
re-observed in the INO1/2 stratification, opens new in-
sights into RNA editing and cancer and also indicated
that can be essential for the identification of
gender-dependent high-risk patients.
Overall, female patients with low AEI (≤ 0.008049) or
lying within the INO-2 subgroup have a better outcome
(see Fig. 6b and Fig. 8b). Interestingly, both these groups
of female patients showed a similar molecular signature
characterized by a high mutation frequency rate (with
TTN and MUC16 being the top mutated genes) and an
enrichment in the LGm6 DNA methylation profile [38]
(Additional file 2: Figure S12).
INO-1 female patients (high-risk patients) showed a
significantly higher editing level compared to the INO-2
group at specific positions (Additional file 6: Table S5).
Among the top editing sites (with at least 15% Δ me-
dians editing differences), we found three positions all
lying within the 3′-UTR (within Alus) of PSMB2. The
PSMB2 transcript codes for the proteasome subunit beta
type 2 and is one of the essential subunits of the
proteasome. Proteolysis plays a major role in cancer
cells, for example, controlling the degradation of tran-
scription factors, such as p53, c-Jun, NF-kB, HIF-1a,
STAT3, androgen receptors, and sterol-regulated
element-binding proteins. Studies on proteasome inhibi-
tors and screening based on small interfering RNA in
GBM highlighted the potential significance of prote-
asome in cancer [39–41]. Interestingly, a high editing
level at these three sites within 3′-UTR of PSMB2 can
potentially alter the binding of specific microRNAs lead-
ing to PSMB2 upregulation in GBM. Accordingly, with
the above observation, we found a significant and direct
correlation between PSMB2 expression and editing only
when female patients were considered (Additional file 2:
Figure S11). Of note, microRNAs can play an important
role in sexually dimorphic neurobiological systems [42],
indicating an intriguing connection between editing
within 3′-UTRs and microRNAs differently expressed in
an hormone-dependent manner.
The intriguing link between RNA editing and
gender-related patient OS may suggest a possible contri-
bution of gender-specific transcription factors or
sex-dependent hormones controlling ADAR expression/
activity at least in cancer. Previous work showed that
editing in fly has some sex-specific differences within the
central nervous system [43]. Indeed, in fly, the authors
reported an overall reduction of editing in female rela-
tive to male heads as observed in fru neurons [43],
which indeed exhibit sexual dimorphism [44]. Interest-
ingly our findings open the possibility that also in the
human brain there are gender-dependent differences in
the overall impact of editing within specific sites and/or
transcripts (i.e., PSMB2).
Another intriguing result of our study is that in nor-
mal individuals, the expression of the active deaminases,
ADAR1 and ADAR2, inversely correlated with patient
age, being less expressed in older individuals. Differently,
ADAR3 displayed the opposite trend, being overex-
pressed in elderly subjects. The latter finding is particu-
larly fascinating because ADAR3 expression correlated
with age only when male individuals were considered.
This link between ADAR expression and age/gender was
lost in GBM patients. Of note, we reported that > 85% of
de novo GBMs carries a deletion involving the ADAR3
genomic locus, a finding that opens the intriguing possi-
bility that this specific event could play a possible role in
GBM. A recent study reported ADAR3 overexpression
in few adult GBMs [7]. Differently, we showed that
ADAR3 is down-expressed in adult GBM due to the de-
letion involving its genomic locus, with only really lim-
ited cancer samples (~ 2.1% of GBMs) carrying a gene
gain/amplification. It is possible that genetic differences
among GBM samples can explain the discrepancies in
different studies.
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An important contribution to GBM research was the
identification of GBM subtypes defined on the basis of
genomic mutations and expression signatures [29, 30].
When we superimpose the RNA editing signature to the
well-known GBM subtypes (with mesenchymal, neural,
classical, and proneural) [29], we found that only 2
groups emerged with the proneural subtype came out as
an independent group and a second GBM group includ-
ing all the remaining subgroups (mesenchymal, neural,
classical). We identified 16 editing sites in 9 different
transcripts, all significantly under-edited in PN. Most of
these sites lay within 3′-UTRs (17/22), indicating that
editing may be linked to gene expression regulation.
Seven sites were localized within MDM2 upstream the
p53-pathway [45]; of note, TP53 mutations and loss of
heterozygosity were frequent events in proneural sub-
type [29].
Overall, our study defined a novel framework in which
editing profiles can play multiple and essential roles in
GBM being important for (i) possible novel diagnosis
(using AEI, nREI, REI, and ADAR3 expression), (ii) an
alternative GBM patient stratification with only two
editing-based subgroups (INO-1 and INO-2), (iii) novel
clinical prognostic factors for GBM patients (i.e., editing
within COG3 I/V and AEI), (iv) eligible target (COG3 I/
V) for personalized therapeutic intervention (i.e., anti-
sense oligonucleotides), and (v) the detection of a novel
high-risk gender-specific patient subgroups for which
more aggressive treatments are necessary.
For many cancer types, men and women are very dif-
ferent in terms of susceptibility, survival, and mortality,
and this is a fundamental issue for cancer prevention
and therapy: however, little is known for GBM [46]. A
recent study revealed that molecular differences in can-
cer between males and females determined strong sex
effects due to mutations, DNA methylation, transcripts,
and protein expression in several cancers but not in
high-grade gliomas [47]. The present study shows, for
the first time, that post-transcriptional events such as
A-to-I RNA editing may play a key role in a
gender-dependent GBM patients stratification that could
be important for the identification of “ad hoc”
sex-related therapies.
Conclusion
Our study presents a comprehensive analysis of A-to-I
RNA editing events in GBM, normal brain, and astro-
cytes and provides the first evidence that RNA editing
plays an important role in patients’ outcome. We
propose that RNA editing at specific recoding sites may
act as a “driver” for tumor growth and that GBM inosi-
nome can be considered for a novel patient stratification
method providing a systematic molecular understanding
of sex differences in GBM.
Methods
Processing of sequence reads
Brain normal controls (132 cerebral cortex), with 39
mean (37 median) millions of reads (paired ends), were
downloaded from the Genotype-Tissue Expression
(GTEx), and primary/de novo GBMs (145 samples), with
48 mean (50 median) millions of reads (paired ends),
were downloaded from The Cancer Genome Atlas
(TCGA). Both libraries, with the same read length (76
bp) and generated from polyaRNA, were downloaded
upon authorization from the database of Genotypes and
Phenotypes (dbGaP) with accession numbers
phs000424.v7.p2 and phs000178.v10.p8, respectively.
Astrocyte dataset was downloaded from the NCBI Se-
quence Read Archive (SRA): SRP064454 study: RNA-Seq
of healthy human astrocytes [48].
Additionally, for the data validation, we also down-
loaded 88 de novo GBMs from the Chinese Glioma
Genome Atlas (CGGA) [24] (read length 101 bp; .fastq)
generated from total RNA (SRP027383 and SRP091303).
TCGA GBM datasets were downloaded in .bam format
and converted in standard .fastq using bam2fastq tool.
GTEx datasets were downloaded in .sra format and con-
verted in .fastq by means of fastq-dump program that is
part of the SRA toolkit package.
Quality control and alignment
Low-quality reads were discarded by filtering with the
NGS QC Toolkit [49] and default parameters (cutoff
read length for HQ = 70%, cutoff quality score = 20).
High quality cleaned reads were mapped against
pre-indexed human genome GRCh37, transcriptome
(pre-processed set of known splice junctions from
Ensembl annotation), and dbSNP common release 144
using HISAT2 version 2.0.4. Unique and concordant
alignments in .sam format were converted in the binary
.bam format, sorted by genomic coordinates, and
indexed by SAMtools.
For RNA-Seq experiments from normal astrocytes
pools, duplicated reads were removed using the Mark-
Duplicates.jar tool from Picard package (https://broadin-
stitute.github.io/picard/).
Detection of A-to-I editing at specific sites
RNA editing events were obtained merging known posi-
tions from RNA Editing ATLAS [10] (http://srv00.recas.
ba.infn.it/editing/) repository and from RADAR version
2 database (http://rnaedit.com/) [50]. Both collections
include A-to-I changes identified using rigorous compu-
tational pipelines. Merging ATLAS and RADAR posi-
tions yielded a comprehensive and non-redundant RNA
editing catalog comprising 4.668.508 sites. The REDI-
tools package (https://sourceforge.net/projects/reditools/)
[51] was employed to call RNA editing events from this
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huge collection of positions. In particular, we used
REDItoolDnaRna.py script to each .bam file by using
the following parameters: -m 60,60 -q 30,30 -T ALLe-
diting.sorted.gtf.gz -G ALLediting.sorted.gtf.gz -e -c
0,0 -n 0.0 -v 0 -p -u -l -z. REDItool tables were then
parsed, and only edited positions supported by at
least ten reads and at least with 1% editing were
retained and used for downstream analyses. Editing
sites that did not achieved the above cutoffs, in at
least two tumor samples and two normal brains, were
considered not informative and discarded.
Alu editing index
Alu editing index (AEI), according to the methodology
described in Bazak et al. [16], measures the averaged
editing rates of adenosines in Alu elements, weighted by
their relative expression levels. It may be quantified by
the ratio of the number of A-to-G mismatches (presum-
ably due to inosines) to the total number of reads nucle-
otides aligned to a genomic adenosine within an Alu
repeat.
To calculate Alu editing index, we collected with
REDItools all the mismatches between the aligned reads
and the reference genome that occur within Alu ele-
ments (annotations for Alu genomic regions were down-
loaded from UCSC genome browser), discarding
mismatches in read positions with quality Phred score <
30 and those located at sites reported as genomic SNPs
in dbSNP (Common SNP build 144).
Non-repetitive editing index—recoding editing index
In order to analyze the editing level in non-repetitive se-
quences and at the recoding sites, we introduced two new
metrics, custom python script (provided as Add-
itional file 8): the non-repetitive editing index (nREI) and
the recoding editing index (REI). nREI and REI were eval-
uated for each normal brain, astrocyte, and GBM sample
as the weighted average of the editing level in all the sites
located in non-repetitive regions and recoding positions.
Gene expression quantification
Transcriptome quantification at gene level was per-
formed for each sample with Cuffquant [52], and differ-
ential expression was tested with CuffDiff2 software
version 2.2.1 [53] (with --dispersion-method
per-condition parameter). Reference human transcrip-
tome was obtained from GENCODE Comprehensive
gene annotation Release 26 back-mapped to GRCh37
(https://www.gencodegenes.org/). Annotations for rRNA
genes were downloaded from UCSC genome browser
selecting the RepeatMask table. Gene expression values
are reported as fragments per kilobase of exon per mil-
lion fragments mapped (FPKM). Transcriptome
signature comparison was conducted by CummeRbund
R package (http://compbio.mit.edu/cummeRbund/).
Statistical analysis
Statistical analyses were performed using R with
pandas and scipy modules in python. Non-metric
multi-dimensional scaling (N-MDS) was carried out
in R using the metaMDS function of the vegan pack-
age, providing as input a Spearman correlation matrix
calculated from editing levels for each sample.
Two-dimensional images depicting MDS clusters,
heatmaps, and box plots were generated by ggplot2
package in R. Kaplan-Meier curves were inferred by
using the R packages “survival,” ggfortify, and “surv-
miner” with log-rank test, and the resulting plots
were customized by applying the R package ggplot2,
(https://ggplot2.tidyverse.org/).
Using the R packages “survival” and “survminer,” uni-
variate and multivariate analyses were performed by ap-
plying the Cox proportional hazard model to assess the
effect of several molecular risk factors (TP53 status, IDH
status, MGMT promoter status, Chr7 Gain/Chr10 loss,
and Alu editing index) on patient OS.
Editing-based glioblastoma reclustering
Two hundred sixty-seven editing sites detected in at
least 140/145 GBM samples (and located in intronic, ex-
onic, and UTRs regions) were selected and used to cal-
culate a sample distance matrix with the vegdist function
(method = “Euclidean”) included in the vegan R package;
the resulting distance matrix was used to perform, with
the hclust R function (method = “ward.D”); an unsuper-
vised hierarchical clustering is shown as a dendrogram
at the top of a heatmap generated with the heatmap.2
and ggplot2 R functions.
Human tissues and cell lines
De novo GBM tumors and control brain tissues (adult
subjects) were dissected and either immediately frozen
(for molecular studies) or embedded in paraffin (for im-
munohistochemistry analysis).
Human GBM cell lines U87-MG, U118-MG, and
A172 were obtained from the American Type Culture
Collection (ATCC) and routinely maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (Gibco-Life Technologies),
100 U/ml penicillin, and 100 μg/ml streptomycin, at 37 °C
in 5% CO2. Mycoplasma contamination was routinely
tested by Venor®Gem OneStep Mycoplasma detection kit
for standard PCR (Minerva Biolabs), and the latest ana-
lysis was performed on February 2018. The cells were uti-
lized between passage numbers 10 and 15.
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Editing activity in cell line
HEK 293T cells were chosen for the assessment of
EGFP-ADAR2 and EGFP-ADAR1 editing activity as the en-
dogenous editing activity in this cell line is undetectable.
Cells were transiently co-transfected independently with
4 μg of EGFP-ADAR2, EGFP-ADAR1, and pEGFP
(V-EGFP) 48 h after transfection; total RNA was extracted
from the cells using TRIzol reagent and reverse-transcribed
by specific primers for edited substrates. Transfection was
tested by both real-time PCR and Western blot.
RNA isolation and reverse transcription
Total RNA was isolated with TRIzol reagent (Invitrogen)
from de novo GBM tumors, control brain tissues (adult
subjects), and cultured cell lines, according to the manu-
facturer’s instructions. The cDNA pools were generated
by SuperScript II reverse transcriptase (Invitrogen) using
random hexamer primers.
Analysis of RNA editing
Direct sequencing was performed on cDNA pools, and
editing was calculated as described previously [54], or
the PCR products were subcloned into the T-easy vector
(Promega), and ~ 50 individual cDNA clones were se-
quenced for each sample. A to G changes in the individ-
ual clones were analyzed. For each sample, 2–3
independent RT-PCR reactions were performed.
GBM cell lines and lentiviral infection
Human GBM cell lines U87-MG, U118-MG, and A172
were obtained from American Type Culture Collection
(ATCC) and routinely maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (Gibco-Life Technologies), 100 U/ml
penicillin, and 100 μg/ml streptomycin, at 37 °C in 5%
CO2. Mycoplasma contamination was routinely tested
by Venor®Gem OneStep Mycoplasma detection kit for
standard PCR (Minerva Biolabs). The cells were utilized
between passage numbers 10 and 15. Lentiviral COG3
expressing vector [ABM LV484109 (pLenti-
GIII-CMV-GFP-2A-Puro)] was purchased from ABM-
GOOD, and site-directed mutagenesis was performed to
generate a lentiviral vector encoding the COG3 edited
version containing an isoleucine-to-valine substitution at
position 635 (I635V). The lentiviral particles were pro-
duced by transfecting human embryonic kidney 293T
(HEK293T) cells with the COG3 unedited or COG3 edi-
ted I635V expression vectors and the Lentiviral Pack-
aging Mix (pREV, pMDL, and VSV.G). The supernatant
was collected after 72 h and concentrated by ultracentri-
fugation at 40,000 rpm for 75′ at 4 °C. Cells were in-
fected, and stable cells were selected with 1 μg/mL
puromycin.
MTS colorimetric assay
Cell proliferation was measured daily by 3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H
-tetrazolium inner salt (MTS) using CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega). Absorb-
ance intensity was determined on a microplate reader at
490 nm. The assay was repeated three times in triplicate.
For statistical analysis, we used the two-sided t test.
Migration assay
Transwell inserts with 8 μm pore size in 24-well plates
(Corning, Life Sciences) were used for migration assays.
1.5 × 104 cells were added to the upper chamber in 0.2
ml serum-free medium; the bottom chamber contained
medium with 10% FBS which acted as cell attractant.
After 24-h incubation, cells that reached the underside
of the filter were stained with Diff-Quik staining set
(Medion Diagnostics) and counted based on five field
digital images taken randomly at × 10 magnification.
Three independent experiments were performed. For
statistical analysis, we used the two-sided t test.
Real-time qRT-PCR
Quantitative real-time PCR (qRT-PCR) was performed
to validate the expression of COG3 in infected cells
using pre-designed stem-loop primers (TaqMan
MicroRNA Assay, Applied Biosystems-Life Technolo-
gies). cDNA was synthesized from 1 μg of total RNA
(pre-treated with DNase I) by the ImProm-II Reverse
Transcription System (Promega) using random hex-
amer primers according to the manufacturer’s
instructions.
GAPDH was used as a control for normalization of
mature mRNAs. The relative amount of COG3 was cal-
culated by the 2−ΔΔCT method. Expression levels were
represented as a relative fold increase compared to the
control sample, which was arbitrarily set to 1. All
qRT-PCR reactions were performed in duplicates, and p
values were calculated (two-sided t test). The primers
were supplied by Applied Biosystems: GAPDH, ID
Hs99999905_m1; COG3 ID Mm00616765_m1.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections (3 μm thick)
were mounted on positively charged glass slides. Deparaffi-
nization and antigen retrieval was performed using the PT
link instrument (Dako) and the EnVisionTM FLEX, low
pH solution (Dako). Endogenous peroxidase was blocked
by hydrogen peroxide (Sigma), and then sections were in-
cubated ON at 4 °C with mouse monoclonal antibody
anti-ADAR3, (3.591): sc-73,410, 1:100 dilution (Santa Cruz
Biotech) followed by EnVision FLEX/HRP (Dako). 3,3′ Di-
aminobenzidine was used as the enzyme substrate to
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observe the specific antibody localization, and Mayer
hematoxylin was used as a nuclear counterstain.
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